Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis

Key Inclusion Criteria: * Participants (or legal guardian/caregiver) with the ability and willingness to sign a written informed consent and/or assent (age appropriate). * Participants of either gender must be at least 2 years to less than (\<) 18 years of age (2 to 17 years, inclusive). * Participants with a clinical diagnosis of tinea corporis characterized by clinical evidence of a tinea infection (at least moderate erythema, mild scaling, and moderate pruritus). * Participants must be in good general health and free of any disease that in the Investigator's opinion might interfere with the study evaluations. * Participants/caregiver must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements. Key Exclusion Criteria: * Participants with active atopic or contact dermatitis in the area to be treated. * Participants with severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection. * Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial. Participants who test positive for pregnancy after start study drug will be discontinued from study drug but will be followed for safety purposes. * Participants who are immunocompromised (due to disease, for example; human immunodeficiency virus \[HIV\] or medications). * Participants who have a recent history of or current drug or alcohol abuse.